heart disease; microarray ATRIAL FIBRILLATION (AF) is a ubiquitous yet diverse cardiac arrhythmia with an overall prevalence of ϳ1% in the general population and up to 8% in patients who are Ͼ80 yr of age (27) . AF is associated with an increased risk of stroke and congestive heart failure (20) . AF is associated with a significant morbidity rate and great costs to both the individual and society (20) . Due to the complex interaction in AF between substrates and stimuli, the precise mechanisms that underlie the onset and persistence of AF have not been completely elucidated (18) . To date, medical interventions for AF are relatively limited (5) .
Mitral stenosis, which is primarily caused by rheumatic heart disease, is among the major cardiovascular diseases in developing countries and in some indigenous populations in developed countries (2) . The incidence of AF in mitral stenosis has been estimated to be 40% (2, 15) . Patients who have both AF and mitral stenosis are relatively young and are at a greater (17.5-fold) risk for stroke compared with people with normal sinus rhythm; patients with both AF and mitral stenosis have a fourfold higher incidence of embolism compared with patients with normal sinus rhythm (10, 16) . The nature of AF in mitral stenosis is multifactorial (2) . Persistent rheumatic inflammation, atrial fibrosis, oxidative stress injury, systemic inflammatory states, autonomic imbalances, and neurohormonal activation can all lead to AF in mitral stenosis cases (2) . AF can also be caused by mitral stenosis; in these cases, AF results from the dysfunction of numerous molecular processes in the body that converge to affect individual tissue responses to stimuli (5) .
MicroRNAs (miRNAs) are small, endogenous, singlestranded, noncoding RNAs that consist of 21-25 ribonucleotides and regulate gene expression via hybridization to messenger RNAs (mRNAs); this leads to the inhibition of mRNA translation or the promotion of mRNA degradation (12, 14) . Interestingly, miRNAs act in a complex functional network in which individual miRNAs can control hundreds of genes and a single gene can be regulated by multiple miRNAs (12) . Because miRNAs are the central players in the regulation of gene expression, they participate in many physiological processes, including cell differentiation, proliferation, mobility, metabolism, apoptosis and stress responses (1) .
Consistent with these multiple roles, it is not surprising that miRNAs regulate key genetic functions in cardiovascular biology and are critical in the pathogenesis of cardiac diseases (17, 28) . Currently, there is a growing body of literature that indicates that a specifically altered pattern of miRNA expression (the miRNA signature) is associated with specific disease processes (26, 29) . miRNA signatures have been reported in various aspects of heart disease, such as hypertrophy, remodeling, heart failure, acute myocardial infarction, and myocardial ischemia-reperfusion injury (21, 23, 25, 26, 28, 29) . However, the miRNA signature in AF, particularly in AF that is associated with mitral stenosis, is still unknown. In the present study, we investigated the miRNA signature in AF with mitral stenosis.
MATERIALS AND METHODS
Human tissue preparations. Approval was obtained from the ethics committee of the Tongji University School of Medicine. The investigation complied with the principles that govern the use of human tissues outlined in the Declaration of Helsinki. All patients provided written informed consent before participating in the study.
Tissue samples (right atrial appendages) from nine healthy controls were obtained from prospective multiorgan donors who did not have cardiovascular pathology in cases in which technical reasons prevented transplantation. Tissue samples were also obtained from 13 patients with mitral stenosis; of these patients, nine had AF and four did not. The tissue samples, which were obtained during heart surgery and were considered to be surgical waste, were immediately shockfrozen in liquid nitrogen and stored at Ϫ80°C until miRNA array analysis. The healthy control group included nine patients, four males and five females, who ranged from 35 to 65 yr old (mean age, 50.63 Ϯ 9.87 yr). The group of mitral stenosis patients without AF included four females, who ranged from 19 to 46 yr old (mean age, 38.21 Ϯ 12.86 yr); two of these patients were treated with beta blockers. The group of mitral stenosis patients with AF included nine patients, two males and seven females, who ranged from 19 to 55 yr old (mean age, 47.89 Ϯ 7.42 yr); six were treated with diuretics, five with digoxin, and two with beta blockers. No significant age differences were observed among the three groups.
In addition, right atrial appendages from four healthy controls, four mitral stenosis patients without AF, and four mitral stenosis patients with AF were collected for validation of the microarray data. These patients were distributed as follows: the four healthy controls included two males and two females, who ranged from 30 to 46 yr old (mean 39.41 Ϯ 4.36 yr); in the mitral stenosis patients without AF group, which included one male and three females who ranged from 18 to 45 yr old (mean 35.91 Ϯ 8.97 yr), one was treated with diuretics, and one was treated with beta blockers; in the mitral stenosis patients with AF group, which included one male and three females, who ranged from 22 to 57 yr old (mean 46.38 Ϯ 8.10 yr); two were treated with diuretics, one was treated with digoxin, and one was treated with beta blockers. No significant age or sex composition differences were observed among the three groups.
RNA isolation and miRNA arrays. The total RNA (including miRNA) was extracted from human right atrium appendages using a mirVana miRNA Isolation kit (Ambion, Austin, TX) according to the manufacturer's instructions for total RNA purification. Briefly, 100 mg of human right atrium appendages were homogenized in 10 vol of lysis/binding buffer. A 1/10 vol of miRNA homogenate additive was added, and the mixture was incubated on ice for 10 min. The total RNA was extracted by adding an equal volume of acid-phenol: chloroform. The RNA quality of each sample was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). miRNAs were labeled using the Agilent miRNA labeling reagent and hybridized to Agilent human miRNA arrays (V2), which included 723 human and 76 human viral microRNAs from the Sanger database v.10.1 (Agilent Technologies, Foster City, CA). The total RNA (100 ng) was dephosphorylated and ligated with pCp-Cy3. Labeled RNA was purified and hybridized to the Agilent miRNA arrays. Hybridization was carried out at 55°C for 20 h; the arrays were washed and scanned using Agilent Scan Control software and were then analyzed with the Agilent Feature Extract software version 9.5.3. Each sample was evaluated in triplicate. The expression threshold was set at the average signal intensity that was detected in samples without input miRNA. miRNA expression data were normalized using a bead-based assay and the locally weighted smooth spline (LOWESS) method. After normalization, all expression values were transformed to a linear scale for statistical comparisons. The MIAME-compliant data were exported to Gene Expression Omnibus (platform ID GPL10701).
Quantitative reverse transcriptase-polymerase chain reaction analysis. To validate the microarray results in the present study, a stem-loop quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) assay based on SYBR Green I was performed on randomly selected deregulated miRNAs (hsa-miR-338-3p, hsa-miR-10a, hsamiR-335, and hsa-miR-370 for comparing mitral stenosis to controls; hsa-338-3p, hsa-miR-10a, and hsa-miR-370 for comparing AF to controls; and hsa-miR-335, hsa-miR-181a, and hsa-miR-181c for comparing AF to mitral stenosis), the most upregulated miRNA (hsa-miR-1202), and the most down-regulated miRNA (hsa-miR-143*). According to the manufacturer's instructions, cDNA was generated using the miScript Reverse Transcription (RT) Kit (Qiagen, Hilden, Germany). Briefly, 1 g of total RNA, 1 l of miScript Reverse Transcriptase Mix, and 4 l of miScript RT buffer were mixed and incubated for 60 min at 37°C. The qRT-PCR was performed using an Mx3000 QPCR System (Stratagene, La Jolla, CA) with the miScript SYBR Green PCR Kit (Qiagen, Valencia, CA). The 20-l PCR reaction contained 2 l of RT product, 10 l of 2ϫ QuantiTect SYBR Green PCR Master Mix, 2 l of 10ϫ miScript Universal Primer, 2 l of 10ϫ miScript Primer Assay (Qiagen), and 4 l of autoclaved distilled water. The reaction protocol was as follows: 95°C for 10 min, followed by 40 amplification cycles of 94°C for 15 s, 55°C for 30 s, and 70°C for 30 s. All qRT-PCR reactions, including the no-template controls, were performed in triplicate. The relative expression ratios of the miRNAs were determined using the crossing point as the cycle number. Two highly conserved and universally expressed small nRNAs, U6 and 5S, were used as endogenous controls. The qRT-PCR amplification products were subjected to melting curve analysis.
Bioinformatic analysis. GOmir was used to identify potential human miRNA target genes. This technique integrates miRNA target prediction and functional analysis by combining the predicted target genes from the TargetScan, miRanda, RNAhybrid, and PicTar 4-way databases and provides a full gene description and functional analysis for each target gene (22) . Only those genes that were predicted by two or more tools were considered to be candidates; the greater the number of databases that predicted that a given gene would be a target, the more likely the miRNA-mRNA interaction would be relevant (30) . Based on the current knowledge about the mechanism of AF, the putative potential targets are listed in Table 3 (7, 18) . In addition to the possibility that individual miRNAs play specific roles in the genesis of AF, the miRNA pathway as a whole may also be of great importance. DIANA-mirPath, which is a web-based computa- Fig. 1 . Unsupervised hierarchical clustering and heat maps of the microRNA (miRNA) microarray data. A: unsupervised hierarchical clustering and heat maps of the miRNA microarray of healthy controls and patients with atrial fibrillation (AF). The miRNA microarray cluster of healthy controls and patients with AF clustered into 2 distinct sets based on signal strength. Sample names are indicated at bottom. The first 9 samples were obtained from healthy controls, and the remaining samples were obtained from AF patients. B: unsupervised hierarchical clustering and heat maps of the miRNA microarray of healthy individuals and mitral stenosis patients. The miRNA microarray of healthy persons and mitral stenosis patients clustered into 2 distinct sets based on signal strength. Sample names are indicated at bottom. The first 9 samples were obtained from healthy controls, and the remaining samples were obtained from mitral stenosis patients. C: unsupervised hierarchical clustering and heat maps of mitral stenosis patients with and without AF based on the miRNA microarray data. The miRNA microarray cluster of mitral stenosis (with and without AF) patients clustered into 2 distinct sets according to their diagnosis based on signal strength. Sample names are indicated at bottom. The first 9 samples were obtained from mitral stenosis patients with AF, and the remaining samples were obtained from mitral stenosis patients without AF. The names of the significantly altered (P value Ͻ0.05) miRNAs are shown at right. http://physiolgenomics.physiology.org/ tional tool that was developed to identify molecular pathways that are potentially altered by the expression of multiple miRNAs, was used to incorporate miRNAs into molecular pathways (19) . Statistical analysis. For the analysis of miRNA array data, one-way analysis of variance was used to determine whether there were any significant differences among the groups. If a significant difference was found, Dunnett's post hoc test was conducted to determine which group differed significantly. P values Ͻ 0.05 were considered to be statistically significant. Significant data were further analyzed by clustering, and the expression profiles were visualized with GeneSpring 10.0 (Agilent Technology). In qRT-PCR analysis, the relative expression level for each miRNA was calculated using the 2-⌬⌬Ct method. To account for possible differences in the amounts of miRNAs, miRNA expression was normalized to U6 and 5S.
RESULTS
miRNA expression signature in mitral stenosis patients with AF and in healthy individuals. miRNA microarrays of the AF patients and healthy individuals clustered into two distinct sets based on signal strength (Fig. 1A) . With the exception of one healthy sample, all samples clustered into their respective groups. As shown in Table 1 , 136 miRNAs were expressed differently in AF patients compared with healthy controls; of the 136 miRNAs, 50 were upregulated, and 86 were downregulated in AF patients compared with healthy controls. The fold-changes of the deregulated miRNAs are displayed in Table 1 .
miRNA expression signature in mitral stenosis patients without AF and in healthy individuals. Unsupervised hierarchic clustering of mitral stenosis and healthy samples was performed on the 96 differently expressed miRNAs in these patient groups. The heat map of the miRNA expression categorized two well-defined clusters that corresponded to samples from patients with mitral stenosis and healthy controls (Fig.  1B) ; of the 96 miRNAs, 77 were upregulated in mitral stenosis patients compared with healthy controls, whereas 49 were downregulated. The fold-changes of the deregulated miRNAs are displayed in Table 2 . miRNA expression signature in mitral stenosis with and without AF. An unsupervised hierarchical clustering analysis based on 28 differently expressed miRNAs showed that the miRNA expression signature could separate these samples based on their diagnosis (Fig. 1C) ; of the 28 miRNAs, eight were upregulated, and 20 miRNAs were downregulated in mitral stenosis patients with AF compared with the mitral stenosis patients without AF. Among these miRNAs, miR-1202 was the most upregulated miRNA, while miR-143* was the most downregulated. The fold-changes of the deregulated miRNAs are displayed in Table 3 .
Validation of the microarray data using qRT-PCR analysis. Independent RNA samples that were prepared in parallel with the samples for the microarray were used. The expression of randomly selected deregulated miRNAs in this profile was validated using qRT-PCR. The relative expression levels of all tested miRNAs (hsa-miR-338-3p, hsa-miR-10a, hsa-miR-335, and hsa-miR-370 for comparing mitral stenosis with control; hsa-338-3p, hsa-miR-10a, and hsa-miR-370 for comparing AF with controls; hsa-miR-335, hsa-miR-181a, and hsa-miR181c for comparing AF with mitral stenosis) correlated well with the values from the microarrays (Table 4) . We also validated the most upregulated miRNA, miR-1202 (Table  4) . However, the most downregulated miRNA, miR-143* could not be validated, which was probably due to its relatively low abundance in the heart. The baseline Ct values for hsamiR-338-3p, hsa-miR-10a, hsa-miR-335, hsa-miR-370, hsamiR-181a, hsa-miR-181c, hsa-miR-1202, and hsa-miR-143* were 30 potential targets based on current knowledge about the underlying mechanisms of AF are listed in Table 3 .
To show that the miRNA pathway as a whole plays a role in the genesis of AF, we first used the dysregulated miRNAs in AF compared with healthy controls to incorporate the potentially affected pathways using DIANA-mirPath. The upregulated miRNAs that were used to incorporate the pathway did not include the following miRNAs because they were not included in the DIANA-mirPath results: miR-320c, miR-33b*, miR-505*, miR-1228, miR-1226*, miR-1225-5p, miR-1249, miR-1181, miR-1915, miR-664*, miR-1471, miR-135a*, miR-1207-5p, miR-1275, miR-1224-5p, miR-513b, miR-1202, miR-1308, miR-149*, miR-30d, miR-18b*, and miR-1268. The potential affected pathways included the following: the MAPK signaling pathway, regulation of actin cytoskeleton, the Wnt signaling pathway, oxidative phosphorylation, the transforming growth factor-beta (TGF-␤) signaling pathway, the mammalian target of rapamycin (mTOR) signaling pathway, the Notch signaling pathway, gap junctions, the calcium signaling pathway, and the VEGF signaling pathway ( Table 5 ). The downregulated miRNAs that were used to generate the pathways did not include the following miRNAs because they were not included in the DIANA-mirPath results: miR-29c*, miR-1305, miR-99a*, miR-22*, miR-29a*, miR-136*, miR-19a, let-7e*, miR-23b*, miR-10a, let-7a*, miR-17*, miR-145*, let7i*, miR-1271, miR-20a*, miR-128, miR-340*, miR-19b, miR-143*, miR-26b*, miR-125b-2*, miR-7-1*, and miR-126*. The potential affected pathways included the following: the Wnt signaling pathway, oxidative phosphorylation, regulation of actin cytoskeleton, the MAPK signaling pathway, the TGF-␤ signaling pathway, the mTOR signaling pathway, gap junctions, and cell communication (Table 6 ). To further reveal the pathway that might specifically contribute to the genesis of AF in mitral stenosis patients, the pathway histograms of the upregulated downregulated miRNAs that were dysregulated in mitral stenosis patients with AF and mitral stenosis patients without AF were incorporated using DIANA-mirPath and are displayed in Fig. 2 and Fig. 3 , respectively. The upregulated miRNAs that were used to generate the pathway histogram did not include miR-1225-5p, miR-1181, miR-1207-5p, and miR-1202 because they were not included in the DIANA-mirPath results. The pathway histogram showed that the regulation of the actin cytoskeleton, the TGF-␤ signaling pathway, and the MAPK signaling pathway might potentially participate in the genesis of AF in mitral stenosis patients (Fig. 2) . The downregulated miRNAs that were used to generate the pathway histogram did not include miR-145*, miR-143*, miR-26b*, and miR-125b-2* because they were not included in the DI-ANA-mirPath results. The pathway histogram revealed that the MAPK signaling pathway, the TGF-␤ signaling pathway, the regulation of the actin cytoskeleton, oxidative phosphorylation, gap junctions, and the VEGF signaling pathway might play potential roles in the development of AF in mitral stenosis patients (Fig. 3) . Based on the difference between the potential affected pathways in mitral stenosis patients with AF and mitral stenosis patients without AF, we speculated that the regulation of the actin cytoskeleton, the TGF-␤ signaling pathway, the MAPK signaling pathway, oxidative phosphorylation, gap junctions, and the VEGF signaling pathway may potentially contribute to AF. We also speculated that the Wnt signaling pathway, the mTOR signaling pathway, the Notch CSDE1, GRM1, PDGFRA, GJA1, NPR2, MAP2K1, GNAI3, TUBA4A, PDGFB, KRAS, GNAS, HTR2C,  ITPR1, PRKG1, SOS1, MAPK7, MAPK3, GRB2, ADCY9, NPR1, ADRB1, PLCB1, PRKCB1, PLCB4,  PRKACB, PDGFC, RAF1, PDGFA, ADCY6  Calcium signaling pathway  2.36  CAMK2D, PDE1C, GRM1, ADRB2, SLC8A2, PDGFRA, SLC25A5, MYLK2, ADRB3, PTGFR, ATP2B4,  EDNRA, ATP2A2, GNAS, ENSG00000143933, VDAC2, SLC8A1, HTR2C, ADORA2B, ITPR1, GRIN1,  ATP2B3, CACNA1D, P2RX7, ATP2B1, ADORA2A, CALM1, CALM2, CALM3, PDE1B, P2RX1,  GRIN2A, ADCY9  VEGF signaling pathway  1.65  PIK3CA, NFATC2, CSDE1, MAP2K1, MAPKAPK3, SH2D2A, KRAS, PLA2G2F, PIK3R1, VEGFA,  NFATC3, MAPK3, CDC42, CASP9, PPP3CA, AKT2, PRKCB1, NFAT5, PIK3R3, AKT3, RAF1 TGF, transforming growth factor; mTOR, mammalian target of rapamycin.
signaling pathway, the calcium signaling pathway, and cell communication might play roles in mitral stenosis.
DISCUSSION
The miRNA expression signature in a given disease paradigm represents a powerful approach for unbiased comprehensive interrogation of the miRNA genome (11) . There are currently no published reports on the miRNA microarray profile of AF, particularly in AF with mitral stenosis. This study is the first to provide evidence that characterizes the global changes in miRNA expression in human right atrial appendages in AF patients with mitral stenosis.
The appropriate pattern of miRNA expression is fundamental to the normal functioning of the cardiovascular system (4, 13) . This study showed the miRNA expression signature of the right atrial appendages of healthy controls and mitral stenosis patients with and without AF. There were 136 and 96 differently expressed miRNAs in the mitral stenosis patients with AF and the mitral stenosis patients without AF, respectively compared with the healthy controls. Mitral stenosis is an important cause of AF (2, 15) . In our study, the miRNA arrays showed that 28 miRNAs that were expressed differently in mitral stenosis with AF compared with mitral stenosis without AF. The unsupervised hierarchical clustering analysis using 28 differently expressed miRNAs showed that the heat map of miRNA expression categorized two well-defined clusters corresponding to mitral stenosis with and without AF. After the quantification of the signal intensity and normalization to U6 or 5S, we found that the results correlated well with the microarray data. miR-133 and miR-590 were recently reported to be downregulated both in AF patients and in a canine AF model, which is consistent with our finding that these miRNAs were downregulated in AF patients compared with healthy controls (8, 24) . However, while the expression miR-1 did not significantly change in our study, it was reported to be reduced in AF in another study (6) . This contradictory finding may reflect the differences in tissues that were sampled (right atrial appendages in the current study vs. left atrial tissue in that study) and the heterogeneity of human myocardial samples (9) .
Several potential limitations of this study should be highlighted. First, because the present study was performed with native human tissues, we did not conduct experiments to modulate the miRNA levels. Thus, the evidence presented here is indirect. Second, the exact targets and pathways by which alterations in miRNAs cause AF in mitral stenosis remain elusive. Although our bioinformatic analysis has indicated some potential targets and pathways that are involved in AF, it is difficult to estimate the actual false-positive rate of the overall target prediction (30) . A better understanding of the biological significance of these broad, but often subtle, changes in miRNA expression that are found in AF patients with mitral stenosis would be ultimately achieved with the development of experimental models in which the levels of one or more miRNAs could be precisely manipulated. This is certainly of great importance and will be an ambitious task for laboratories around the world for many years. Such research may lead to therapeutic interventions that are based on rational target selection in AF patients with mitral stenosis (3).
In conclusion, the current study described the miRNA expression signature in human AF with mitral stenosis. The Wnt signaling pathway  18.54  FZD7, CTNNBIP1, AXIN2, CXXC4, WNT3A, CAMK2D, WNT2B, DAAM2, CUL1, GSK3B, WNT4,  NFATC2, MAPK8, PRKCA, NKD1, LEF1, DVL3, WNT3, MYC, CSNK2A2, WNT16, FZD5,  DOCK5, PPP2R2B, PPP3CC, LRP6, TBL1X, PPP2R1A, RHOA, ROCK1, WNT5B, PRKACA pattern of dysregulated miRNAs in AF with mitral stenosis potentially contributes to the biological understanding of AF. In addition, the miRNA expression signature described in this study provides potential targets for future clinical applications (4, 9). Fig. 2 . The pathway histogram of the upregulated miRNAs in AF with mitral stenosis that were incorporated using DIANA-mirPath. The upregulated miRNAs that were used to generate the miRNA pathway include hsa-miR-188-5p, hsamiR-212, hsa-miR-335, and hsa-miR-630. Fig. 3 . The pathway histogram of the downregulated miRNAs in AF with mitral stenosis that were incorporated using DIANA-mirPath. The downregulated miRNAs that were used to generate the miRNA pathway include hsa-miR-874, hsa-miR-181b, hsa-miR-145, hsa-miR-550, hsa-miR-500, hsa-miR-149, hsa-miR-181a, hsa-miR-95, hsa-miR-181c, hsa-miR-125a-5p, hsa-miR-181d, hsa-miR-501-5p, hsa-miR-324-5p, hsa-miR-497, and hsa-miR-125b.
